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neutrophil count  0.5109 /L was 14 and Median time of
platelet recovery 20109 /L was 25. At present 42 out of 52
are alive and 10 patients died due to acute GVHD, chronic
GVHD, rejection, veno-occlusive disease, infection and the
others. Thirty-four patients (64%) developed acute GVHD
(grade I  13, grade II  7, grade III 10, grade IV 4). Three
patients (5.8%) developed chronic GVHD (limited 2, exten-
sive 1). 8-year disease free survival were 73.17%. 8-year over-
all survival were 79.85%.
Conclusion: According to this study, for an acceptable out-
come in Thalassemia class 3We need better conditioning and
GVHD prophylaxis regimens to decrease cardiopulmonary and
liver complications. The results of blood and marrow transplan-
tation showed that it is better than supportive therapy such as
transfusion and desferal therapy.
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OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA IN
SECOND COMPLETE REMISSION, SINGLE CENTRE EXPERIENCE
Ishaqi, M.K.1, Afzal, S.1, Doyle, J.1, Gassas, A.1 1Division of Haema-
tology/Oncology/Bone Marrow Transplantation, Hospital for Sick Chil-
dren, University of Toronto, Canada, Toronto, ON, Canada.
Allogeneic hematopoietic stem cell transplantation (HSCT) is
proven to be an effective modality of treatment for children with
high risk or relapsed acute myelogenous leukemia (AML). Sur-
vival rate as high as 72% has been reported when offered to
patients in ﬁrst complete remission (CR1). The outcome for
children transplanted in second complete remission is less
favourable with reported survival ranging from 40 to 58%. We
reviewed 26 consecutive pediatric patients with AML who re-
ceived allogeneic HSCT in CR2 between 1994 and 2005 in the
Hospital for Sick Children, Toronto, Canada. Twenty-two pa-
tients transplanted in CR2 after chemotherapy only relapse and
4 patients suffered relapse after ﬁrst allogeneic transplant and
received second allogeneic HSCT in CR2. Conditioning regi-
mens included cyclophosphamide 50mg/kg infused over 1 hour
daily for 4 days and fractionated total body irradiation (TBI;
1200cGy) in six fractions over 3 days (CY/TBI) in 13 patients,
2 patients received Busulfan infused every 6 hours for 4 days
followed by cyclophosphamide 50mg/kg infused over 1 hour
daily for 4 days (Bu/CY), 5 patients received ATG in addition to
the Bu/CY regimen and 6 patients received other conditioning
regimens. Median age at transplant was 8.3 years (range 2.2-18.2
years). Four patients received matched sibling donor (MSD), 5
patients received one antigen mismatched related donor
(MMRD), 16 patients received unrelated donors and 1 patient
received unrelated cord progenitor stem cells. Primary graft
failure was encountered in 2 patients, 1 patient was re-trans-
planted successfully and remains alive in remission and the other
patient died of sepsis and respiratory failure. The rest of the
patients engrafted at a median of 20 days (range 10-35 days).
Acute grade III-IV and chronic GVHD occurred in 9 patients
(35%). Six patients (23%) suffered relapse, 4 of them died and
two are still alive at 2495 days and 2944 days with donor
leukocyte infusion (DLI) and second transplantation, respec-
tively. Six patients (23.0%) died from TRM. Including the 2
relapsed patients who were salvaged by DLI and a second
transplantation, survival was 62% with a median follow-up of
1198 days (range 53-4014 days). Conclusion: Survival for chil-
dren transplanted in CR2 for AML is higher than previously
reported, but relapse and treatment-related mortality remains a
concern.
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NOVEL TYROSINE KINASE INHIBITOR THERAPY (NTKI) PRIOR TO
ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS
WITH CHRONIC MYELOID LEUKEMIA (CML): NO EVIDENCE FOR IN-
CREASED TRANSPLANT-RELATED TOXICITY
Jabbour, E.1, Cortes, J.1, Kantarjian, H.1, Giralt, S.1, Champlin, R.1,
de Lima, M.1 1University of Texas/MD Anderson Cancer Center,
Houston, TX.
Introduction: Patients undergoing ASCT for CML are increas-
ingly likely to have received a NTKI after failing imatinib mesy-
late. It is unknown whether the use of these NTKIs prior to ASCT
increases transplant-related toxicity.
Methods: We retrospectively analyzed the outcome of 12 pa-
tients with CML (1 chronic phase, 6 accelerated phase, and 5 in
blastic phase) who received dasatinib (n2), nilotinib (n7), or
both (n3) prior to ASCT.
Results: Median age was 41 years (range, 18-59 years). The
median time on treatment was 134 days (range, 30-285 days), and
the median time from the end of NTKI therapy to ASCT was 34
days (range, 7-130 days). Preparative regimen was ablative in 8
patients and non-ablative in 4. Source of stem cells were matched
related donors in 7 patients, matched unrelated in 3, haplo-iden-
tical in 1, and unrelated cord blood in 1. All patients engrafted
within 13 days. There was no signiﬁcant early transplant-related
toxicity: gastro-intestinal toxicities of grade 3 were encountered in
2 patients. One patient had secondary graft failure after 6 months
from the ﬁrst ASCT that required a second ASCT. Acute graft
versus host disease (GVHD) of grade 2 was observed in 7 patients
(58%), chronic GVHD in 6 (50%). Nine patients achieved a
molecular response: four complete and ﬁve major (Q-PCR
0.05%). Three patients had disease progression by day 30 post
ASCT. Two patients have relapsed after a median of 12 months
(range, 6-18 months). After a median follow-up of 10 months
(range, 3-22 months), 7 patients are alive in molecular response
and 5 patients died, 4 of disease progression and one of extensive
chronic GVHD.
Conclusion: Previous treatment with NTKI did not increase
transplant-related toxicity in this preliminary experience. Further
follow-up and larger number of patients will be necessary to con-
ﬁrm these observations.
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A MIND AND PHYSICAL FITNESS PROGRAM IN CANCER CARE – FEA-
SIBILITY OF A MULTIMODAL EXERCISE AND PSYCHO-EDUCATIONAL
INTERVENTION FOR PATIENTS UNDERGOING ALLOGENEIC STEM CELL
TRANSPLANTATION. A RANDOMIZED CONTROLLED PILOT STUDY
Jarden, M.1,3, Hovgaard, D.2, Boesen, E.3, Adamsen, L.1 1The Uni-
versity Hospitals Center for Nursing and Care Research, University
Hospital of Copenhagen, Copenhagen, Denmark; 2University Hospital of
Copenhagen, Department of Hematology, Copenhagen, Denmark;
3Danish Cancer Society, Copenhagen, Denmark.
Background: A pilot study incorporating a multimodal ﬁtness
and psycho-educational program to patients undergoing allogeneic
stem cell transplant (allo-HSCT). The main focus of the study is to
evaluate the feasibility, safety and effectiveness of a 4-6 week
intervention consisting of a ﬁtness program with progressive sta-
tionary bicycle-, muscle strength-, ﬂexibility- and relaxation train-
ing and a cognitive based supportive and educational intervention.
The aim of the study was to prevent or minimize loss of physical
capacity and improve overall well being during hospitalization.
Patients and methods: 20 adult patients (18 -65 years) were
randomized to either an intervention or control group using the
clinical international trial management system.Through triangula-
tion of qualitative and quantitative methods, patients are inter-
viewed, tested for physical capacity (VO2 max, muscle strength and
physical functioning), quality of life (EORTC, HADS, Fact-An
and Mini-mac) prior to admission and upon discharge. Patients
kept training journals and registered side effects during hospital-
ization. This study reports only the ﬁndings from the physical
capacity tests.
Results and Conclusion
Of the 22 eligible patients who met the eligibility criteria, 20
agreed to participate (90.9%).14 of 20 patients (70%) completed
all study requirements. In the intervention group, 6 of 9 patients
completed all study requirements (66.7% retention rate). Ad-
herence to the intervention showed that patients trained 94% of
the total expected training days. No adverse reactions or events
that can be attributed to either the testing or exercise program
were reported or observed. Pre test scores showed similiar
values in both groups for all physical capacity tests. Upon
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discharge, there was a signiﬁcant difference found between the
two groups for three muscle tests; chest press (p.023), leg
extension (p.007) and the isometric right knee ﬂexor test
(p.033). Though signiﬁcant values were not reached on all
tests, the differences between the pre- and post-scores of the
two groups for all physical capacity tests are between 16% and
35%, suggesting that the intervention was efﬁcient in prevent-
ing loss of and maintaining physical capacity.
Findings revealed that exercising patients during hospitalization
for allo-HSCT was feasible, safe and effective. In conclusion,
preventative and anticipatory interventions can minimize physical
and functional loss during hospitalization for allo-HSCT.
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CO-STIMULATORY MOLECULE EXPRESSION BY TRANSPLANTED DO-
NOR APC AND HOST CD4 T CELLS IS REQUIRED TO ELICIT RESISTANCE
AGAINST MHC-MATCHED HEMATOPOIETIC ALLOGRAFTS FOLLOWING
REDUCED INTENSITY CONDITIONING
Jones, M.1, Blazar, B.P.2, Zimmerman, Z.1, Levy, R.B.1 1University of
Miami Miller School of Medicine, Miami, FL; 2University of Minne-
sota, Minneapolis, MN.
Circumventing host resistance to hematopoietic progenitor
cell grafts is crucial for successful engraftment and the induc-
tion/maintenance of immune tolerance. We are studying the
regulation of pathways that lead to T cell resistance in recipients
transplanted with MHC-matched allogeneic BM (“MiHA-mis”)
following reduced intensity conditioning (RIC). To examine the
involvement of CD80/CD86 expression in this resistance,
CD80 and CD86 mabs were administered to B6 (wt) BMT
recipients. Donor BALB.B BM was not rejected in these recip-
ients. To investigate the requirement of CD80/86 expression on
recipient cells with respect to development of resistance, BM
was transplanted into wt or B6-CD80-/-86-/- mice. Donor chi-
merism in both recipients was transient indicating resistance
had been elicited against the donor BM. CD80-/-86-/- BM was
then transplanted into “MiHA-mis” recipients following RIC.
In contrast to wt BM grafts, transplantation of CD80-/-86-/- BM
resulted in sustained donor chimerism. Since “MiHA-mis” BM
transplants into CD4-/- recipients demonstrated CD4 cell func-
tion is critical for resistance in this model, we hypothesized that
host CD4 cell recognition of donor APC results in the upregu-
lation of CD80/CD86 co-stimulatory molecules. WT and
CD40L-/- mice were transplanted with BALB.B BM and as
predicted, wt recipients rejected the donor BM. In contrast,
CD40L-/- recipients exhibited stable chimerism. To examine
the requirement of CD40L on CD4 cells in the host, CD4-/-
mice were transplanted with BM together with CD4 cells from
wt or CD40L-/- mice. Recipients co-transplanted with wt CD4
cells rejected their grafts whereas recipients of CD4 cells from
CD40L-/- donors expressed donor cell chimerism and failed to
resist the MHC-matched BM allograft. We interpret the ﬁnd-
ings to demonstrate a requirement for host CD4 cells to recog-
nize donor MiHA and undergo alloantigen induced activation
resulting in CD40L induction of CD80/86 on donor APC.
These interactions subsequently result in host CD8 cell effector
activity inhibiting donor engraftment. Since recipients contain-
ing anti-donor speciﬁc CD8 memory cells were found to resist
MHC-matched HCT containing CD80-/-86-/- APC, these ﬁnd-
ings support the notion that direct recognition of donor APC is
crucial to elicit T cell mediated resistance to hematopoietic
engraftment in naive RIC MHC-matched allogeneic recipients.
Ex vivo mab treatment of donor BM is being examined as a
potential translational application.
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LOW RATES OF CHIMERISM OCCUR WHEN ALEMTUZUMAB IS ADDED
TO CONDITIONING THERAPY FOR NON-MYELOABLATIVE ALLOGENEIC
STEM CELL TRANSPLANTATION
Kasner, M.1, Loren, A.1, Stein, S.1, Goldstein, S.1, Luger, S.1,
Nasta, S.1, Perl, A.1, Schuster, S.1, Tsai, D.1, Andreadis, B.1,
Smith, J.1, Cole, S.1, Hinkle, J.1, Pillai, P.2, Emerson, S.1,
Stadtmauer, E.1, Porter, D.1 1University of Pennsylvania Cancer Cen-
ter, Philadelphia, PA; 2Pennsylvania Hospital, Philadelphia, PA.
Non-myeloablative allogeneic stem cell transplantation (NST)
aims to harness the graft-versus-tumor (GVT) effect while min-
imizing regimen-related toxicity, and relies on donor engraft-
ment to induce remission. The most appropriate GVHD pro-
phylaxis and preparative regimen in this setting remains poorly
deﬁned, though accumulating evidence suggests that full donor
chimerism is associated with maximal GVT effects and protec-
tion from relapse. Previously we found a high rate of donor
chimerism but a high incidence of severe GVHD using ﬂudara-
bine (ﬂu)/cyclophosphamide (Cy) conditioning and cyclospor-
ine (CSA)/mycophenolate moftil (MMF) as GVHD prophylaxis.
Subsequently, methotrexate (MTX) was substituted for MMF
and alemtuzumab (100 mg over 5 days, days -9 to -5) has been
added to our conditioning therapy in an attempt to both deplete
host antigen-presenting cells as well as infused donor T cells
and therefore minimize GVHD. Here we describe 55 patients
who received NST; 23 were conditioned with chemotherapy
alone and 33 were conditioned with alemtuzumab in addition to
ﬂu/Cy (n31) or ﬂu/melphalan (n2). All received CSA/MTX
post-transplant. The median age at NST was 50 years. Indica-
tions for transplant were Hodgkin’s disease (13), NHL (22),
MDS (7), CLL (5), myeloma (5) and 1 each with AML, breast
cancer, and and ovarian cancer. Most patients were heavily
pretreated and 62% had relapsed disease after prior autologous
SCT. There were no signiﬁcant differences between the groups
that did and did not receive alemtuzumab. Donor chimerism
was evaluated in all patients. 36% of patients conditioned with
alemtuzumabhad sustainable chimerism over 90%, and 42%
attained donor chimerism over 50%. This was signiﬁcantly
lower than in patients conditioned without alemtuzumab; 77%
and 82% had sustainable donor chimerism 90% and 50%
respectively (p0.005). There was no signiﬁcant difference in
median survival between patients treated with (12 mo) and
without (16 mo) alemtuzumab (p0.36). Relapse rates appeared
higher with alemtuzumab-containing regimens. Alemtuzumab
at this dose and schedule markedly decreased the incidence of
severe GVHD, but resulted in a higher incidence of graft-
rejection and hence lower rates of full and mixed donor chimer-
ism. Since full donor chimerism may be associated with freedom
from relapse, alternative conditioning regimens, and alternative
dosing and schedule of alemtuzumab administration (to deplete
host APC without in-vivo T cell depletion of the donor graft)
are being explored.
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OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKE-
MIA
Kennedy-Nasser, A.A.1, Arce, J.1, Leung, K.S.1, Gottschalk, S.1,
Bollard, C.M.1, Heslop, H.E.1, Brenner, M.K.1, Krance, R.A.1 1Center
for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s
Hospital, The Methodist Hospital, Houston, TX.
Although allogeneic hematopoietic stem cell transplantation
(HSCT) from an HLA-matched sibling offers curative therapy
for the small numbers of children who develop chronic myeloid
leukemia (CML), less than one third of patients have an appro-
priately matched sibling. Alternative donor transplantation has
had a higher procedure-associated risk, particularly for graft-
versus-host disease (GVHD). We have attempted to reduce
these risks by incorporating alemtuzumab (Campath 1H) into
the preparative regimens for alternative donor grafts. Between
1996 and 2006, 19 pediatric CML patients were transplanted
using either matched sibling (MSD; n  9) or alternative donor
(AD; 5 matched unrelated; 2 mismatched unrelated; 3 mis-
matched related). All recipients of MSD grafts were in chronic
phase at the time of transplant as were 6 of the AD recipients;
three of the AD recipients were in accelerated phase and 1 in
chronic phase presenting in lymphoid blast crisis at the time of
transplant. All recipients received myeloablative conditioning
consisting of cyclophosphamide 45mg/kg x 2, cytarabine arabi-
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